WallStreetZenWallStreetZen

How to Buy Mineralys Therapeutics Stock

Mineralys Therapeutics Inc

Mineralys Therapeutics, Inc. , a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases.

Mineralys Therapeutics stock last closed at $13.09, up 2.27% from the previous day, and has decreased 3.25% in one year. It has overperformed other stocks in the Biotechnology industry by 0.15 percentage points. Mineralys Therapeutics stock is currently +123.76% from its 52-week low of $5.85, and -26.05% from its 52-week high of $17.70.

As of May 2, 2024, there are 49.63M MLYS shares outstanding. The market value of MLYS is $649.67M. In the past 24 hours, 113,802 MLYS shares were traded.

How to Buy Mineralys Therapeutics Stock

Not sure how to invest in Mineralys Therapeutics stock? Here's how.
  1. Decide where to buy Mineralys Therapeutics stock: You need to pick a stock brokerage, but don't worry - we've analyzed dozens of stock brokerages and apps to help you choose where to buy Mineralys Therapeutics stock.
  2. Open your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've selected.
  3. Put funds into your brokerage account: Select your payment method and add your info.
  4. Analyze Mineralys Therapeutics stock: The Mineralys Therapeutics ticker symbol is MLYS. Is Mineralys Therapeutics stock a good investment? Should you buy shares of MLYS? How do MLYS's underlying business fundamentals look? Do top analysts think Mineralys Therapeutics is a good buy? Why has MLYS's stock price moved recently? (Hint: Our stock research tools can help you decide if MLYS is a good stock to buy).
  5. Place your MLYS purchase: Decide if you will purchase MLYS shares at the current market price or use a limit order to buy MLYS shares at a given price.
  6. Get the latest news on your MLYS investment: Create a watchlist to the latest updates on your position in Mineralys Therapeutics stock.

Step 1: Decide where to buy Mineralys Therapeutics stock

You will need a brokerage account to access the NASDAQ market and buy MLYS stock.

A brokerage account is an investment account that allows you to buy and sell a variety of investments, such as stocks, bonds, mutual funds, and ETFs.

Our recommended brokerage: eToro

Based on our experience, eToro is the best stock brokerage. Here's why:

  • Invest in stocks with 0% commissions: Invest without commissions.
  • Buy fractional shares: Even if you can't afford a full share, you can still buy the stock.
  • Access to global financial markets: From Tech to Healthcare, New York to Shanghai — you can fill your portfolio with stocks from the globe's leading stock exchanges.
  • Social investing: eToro has a community of more than 20 million users globally. Talk to, learn from, and copy the unique crypto portfolios of top investors.
  • Security: eToro is a regulated and licensed fintech leader.
  • Buy other assets: Such as ETFs and cryptos.

Get $10 towards your purchase of stock by creating an account with eToro now.

Open eToro Account
eToro securities trading is offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency is offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. https://www.wallstreetzen.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD.

Step 2: Open your brokerage account

Now that you've chosen the right brokerage, you'll need to fill out some personal information so you are able to buy MLYS today.

How to Create a New Brokerage Account on eToro

  1. Click here to get started.
    eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
  2. Enter your personal data to open your new brokerage account.
  1. Send your details by pressing the "Create Account" button.
  2. Get started with eToro today
    eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.

Step 3: Put funds into your brokerage account

Now that you've finished signing up on a good online stock trading app, you need to deposit funds:

Watch this video walkthrough to see the process of transferring funds into your brokerage account.

Get started with eToro today
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.

Step 4: Analyze Mineralys Therapeutics stock

After you have selected the best place to buy Mineralys Therapeutics stock, it's critical to analyze their stock before you buy, so you truly wrap your head around the risk and opportunity.

Mineralys Therapeutics quick stats

MLYS Price
$13.09
1w %
18.57%
1y %
-3.25%
5y %
N/A
P/E
-6.58x
P/B
2.69x
P/S
N/A
PEG
N/A
Revenue
$0.00
Earnings
-$71.90M
Fore. Rev. Growth
N/A
Fore. Earn. Growth
N/A
Market Cap
$649.67M
Next Earnings
May 13, 2024
Next Dividend
N/A

MLYS Due Diligence Checks

WallStreetZen was designed to help part-time investors perform better fundamental analysis in minutes instead of hours.

You can view all of the due diligence checks on MLYS's stock page.

Is MLYS stock properly valued?

Analysts use many financial metrics, analyses, models, and charts to gauge MLYS's fair value.

Using relative valuations measures:

  • MLYS may be undervalued based on its P/B ratio of 2.69x, relative to Biotechnology industry P/B ratio of 5.99x

You can do more valuation analysis on MLYS's stock here.

MLYS Financial Summary

Positive Health Checks:

  • MLYS has a low debt to equity ratio of 0.04.
  • There are more short-term assets than short-term liabilities on the MLYS balance sheet.
  • MLYS has cash burn of 81173000. It has enough cash and short-term investments to cover this for at least one year.
  • There are more short-term assets than long-term liabilities on the MLYS balance sheet.

Negative Health Checks:

  • MLYS has $236.57M in cash and short term investments. This is not sufficient to cover its annual cash burn of $81.17M.

Do analysts think it's a good time to buy MLYS stock

Out of 1 Equities analysts who track MLYS, the consensus analyst rating on MLYS is a Strong Buy

Please keep in mind that analyst forecasts are not stock recommendations, nor are they investment advice.

You can dig deeper into what analysts are saying on the Mineralys Therapeutics stock forecast page.

MLYS Technical Indicators

SMA10
11.86
SMA20
12.21
SMA50
13.14
SMA100
11.67
SMA200
10.97
MACD
-0.14
MACD Signal
-0.33
MACD Histogram
0.19
RSI
57.81
Stochastic %K
74.94
Stochastic %D
67.21
StochRSI %K
98.22
StochRSI %D
96.14

Latest Insiders Trades at MLYS

Over the last year, insiders at MLYS have bought more shares than they have sold.

David Malcom Rodman, Chief Medical Officer of MLYS, was the latest MLYS insider to buy. They bought $6,856.92 worth of MLYS shares on Apr 12, 2024.

Get more info about who owns MLYS shares here.

Does MLYS stock generate passive income?

No, Mineralys Therapeutics doesn't provide an income stream by paying out dividends.

Get opinions from other traders

One of the primary reasons eToro is our highest-rated brokerage is because of its social trading community.

Click below to find out what other community members have to say.

Step 5: Place your MLYS purchase

There are two primary order types:

  • Market order: A market order is an order to buy or sell a security at the best possible price.
    Market orders are usually the easiest way to buy.
  • Limit order: A limit order enables you to buy or sell a security at a specific price (or better).
    If you want to be sure you're buying or selling at a particular dollar amount limit, place a limit order.

Click the Open Trade button and your broker will execute the order.

If you want additional help with investing in stocks on eToro, watch the helpful video below:

Open eToro Account

Step 6: Get the latest news on your MLYS investment

Now that you own some MLYS shares, you'll want to stay up-to-date on your new stock purchase.

Start a watchlist to keep tabs on your MLYS stock.

MLYS Feed

How to Buy Stock in Mineralys Therapeutics

To summarize, here are the 6 steps you need to take to buy Mineralys Therapeutics stock right now:

  1. Decide where to buy Mineralys Therapeutics stock
  2. Open your brokerage account
  3. Put funds into your brokerage account
  4. Analyze Mineralys Therapeutics stock
  5. Place your MLYS purchase
  6. Get the latest news on your MLYS investment

If you are looking for a brokerage, eToro is our recommended option.

Get Started with eToro Today
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.

If you want to track your new investment in Mineralys Therapeutics, add MLYS to your watchlist below.

NASDAQ: MLYS
$13.09+0.29 (+2.27%)
Updated May 2, 2024
Open eToro Account
NASDAQ: MLYS
$13.09+0.29 (+2.27%)
Updated May 2, 2024
Open eToro Account

FAQ

How much does it cost to buy one Mineralys Therapeutics share?

As of May 2, 2024, it costs $13.09 to buy one share of Mineralys Therapeutics stock.

Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $6, you can buy 0.458 shares of MLYS.

Get Started with eToro Today
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.

Is now a good time to buy Mineralys Therapeutics stock?

According to 1 Wall Street analysts who monitor Mineralys Therapeutics, their consensus recommendation is to buy Mineralys Therapeutics stock.

What is the best way to buy Mineralys Therapeutics stock?

One way to place an order for Mineralys Therapeutics stock is with a brokerage account.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.